Abstracts tagged "citrullinated vimentin and rheumatoid arthritis (RA)"

Abstract Number: 1858 • 2018 ACR/ARHP Annual Meeting
An Assay Panel Combining Anti-Protein Arginine Deiminase 4 with Rheumatoid Factor Isotypes Distinguishes Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis
Thierry Dervieux¹, Laura Martinez Prat², John Conklin¹, Claudia Ibarra¹, Michael Mahler², Michael E Weinblatt³ and Joel Kremer⁴, ¹Exagen Diagnostics, Inc., Vista, CA, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Anti-citrullinated peptide antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) but lack sensitivity. We evaluated autoantibodies to protein-arginine deiminase 4 (anti-PAD4) in distinguishing…
Abstract Number: 573 • 2016 ACR/ARHP Annual Meeting
Synovial Fibroblast-Neutrophil Interactions Promote Pathogenic Adaptive Immunity in Rheumatoid Arthritis
Carmelo Carmona-Rivera¹, Erica Moore², Nithya Lingampalli³, Hannes Uchtenhagen⁴, Eddie James⁵, Kevin L. Bicker⁶, Heidi Wähämaa⁷, Victoria Hoffmann⁸, Anca I Catrina⁷, Paul Thompson⁹, Jane H. Buckner⁵, William Robinson¹⁰, David Fox¹¹ and Mariana Kaplan², ¹Systemic Autoimmunity Branch/ NIAMS, National Institutes of Health, Bethesda, MD, ²Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Middle Tennessee State University, Murfreesboro, TN, ⁷Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁸Division of Veterinary Resources, National Institutes of Health, Bethesda, MD, ⁹University of Massachusetts, Worcester, MA, ¹⁰Stanford University School of Medicine, Stanford, CA, ¹¹Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI
Background/Purpose: Methods: Results: Conclusion:
Abstract Number: 962 • 2015 ACR/ARHP Annual Meeting
Profiling at the Single-Cell Level Reveals Evidence for Antigen-Driven Oligoclonal Expansion of Citrullinated Vimentin-Specific CD4+ T Cells in Peripheral Blood of Rheumatoid Arthritis (RA) Patients
Soi Cheng Law¹, Hendrik Nel¹, Jamie Rossjohn^2,3, Hugh H Reid³, Nicole L La Gruta⁴ and Ranjeny Thomas¹, ¹The University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Australia, ²Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff, England, ³Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Melbourne, Australia, ⁴Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia
Background/Purpose: RA is associated with shared epitope (SE)+ HLA-DRB1 alleles, including HLA-DRB1*0401, and development of anti-citrullinated protein autoantibodies. The preferential binding of citrullinated vimentin to…
Abstract Number: 1679 • 2015 ACR/ARHP Annual Meeting
Vicm Is a Novel Biomarker of Macrophage Activity Evaluated in a Phase IIb Clinical Trial of Mavrilimumab
Anne C. Bay-Jensen¹, Xiang Guo², Joachim Høg Mortensen¹, Morten Asser Karsdal¹ and Wendy White², ¹Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease driven by chronic inflammation, upheld by sustained recruitment and infiltration of leucocytes, especially macrophages. Mavrilimumab is a…
Abstract Number: 442 • 2014 ACR/ARHP Annual Meeting
Anti-Carbamylated Protein Antibody Levels Are Elevated in Seropositive Rheumatoid Arthritis and Correlate with Anti-Sa/Citrullinated Vimentin Antibody Levels
Gregory J. Challener¹, Jonathan D. Jones², B. JoNell Hamilton¹, Gilles Boire³, Artur José de Brum-Fernandes⁴, Pierre Cossette⁵, Patrick Liang³, Ariel Masetto⁶, Nathalie Carrier⁷, Henri A. Ménard⁸ and William F.C. Rigby⁹, ¹Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, ²Rheumatology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Médecine, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Internal Medicine Departement, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Rheumatology, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁷Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸Rheumatology, Research Institute of the McGill University Health Center, Montreal, QC, Canada, ⁹Rheumatology; Microbiology and Immunology, Geisel School of Medicine at Dartmouth College, Lebanon, NH
Background/Purpose: Recent studies indicate that the breach of immune tolerance that occurs in rheumatoid arthritis (RA) extends beyond the citrullination of arginines (as recognized by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].